Anand Rathi's research report on Sharda Cropchem
Healthy, 13% y/y, volume growth and market-share gains in its key regions drove Sharda Cropchem’s Q1 results. Growth improved on the back of better demand scenario particularly in Europe and a near complete destocking across major regions. Ahead, we believe prices have bottomed out & volumes would improve as the company expands its reach, penetrating current markets and entering new ones. Further, concerns about the USChina trade war are now subsiding, providing stability to organic growth. That said, we expect 14/25/30% revenue/EBITDA/PAT CAGRs over FY25-28. We introduce FY28e and roll forward our valuation to H1 FY28.
Outlook
We retain a Buy recommendation, with a higher TP of Rs1,250 (earlier Rs770), on 18x H1 FY28e EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
